(IN BRIEF) Roche presented promising 96-week data from the Phase II FENopta study, showing that its investigational drug, fenebrutinib, significantly reduced relapse rates and prevented disability progression in patients with relapsing multiple sclerosis (RMS). The study revealed an annualized relapse … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Bruton’s tyrosine kinase, BTK inhibitor, clinical data, clinical research, clinical trial, data, disability, disability progression, fenebrutinib, FENopta, Levi Garraway, multiple sclerosis, Phase II, relapse rates, relapsing multiple sclerosis, RMS, Roche, treatment
(IN BRIEF) The European Investment Bank (EIB) has granted a €4.7 million EU-backed loan to support the reclamation of the Hrybovychi landfill in Lviv, Ukraine. This funding will help improve waste management infrastructure, address environmental hazards, and transform the landfill … Read the full press release
Posted in Banks, Business, Economy, Environment, Financial, Government, Industrial, Infrastructure & Utilities, Investment, Luxembourg, Management, News, Technology, Ukraine
Tagged Andriy Sadovyi, drainage layer, EBRD, EIB, environmental challenges, Environmental Safety, EU environmental standards, EU-backed financing, European Bank for Reconstruction and Development, European Investment Bank, firefighting, green space, green zone, groundwater monitoring, Hrybovychi landfill, international partners, Lviv, Lviv city budget, Oleksii Kuleba, park area, partnership, perennial grasses, Phase I, Phase II, recreational area, rehabilitation, reservoir, soil covering, surface water treatment, sustainability, sustainable infrastructure, Teresa Czerwinska, Ukraine Municipal Infrastructure Programme, UMIP, Valdis Dombrovskis, waste management, waste management challenges, €6.04 million loan
(IN BRIEF) GSK has reported positive results from its phase II trial for an mRNA seasonal influenza vaccine candidate, showing strong immune responses against influenza A and B strains in both younger and older adults. The trial met success criteria … Read the full press release
Posted in Business, Financial, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged flu vaccine, GSK, mRNA, Phase II, Phase III, safety, Tony Wood
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?